{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:40:25Z","timestamp":1774939225101,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:00:00Z","timestamp":1715472000000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.canrad.2022.11.002","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:39:20Z","timestamp":1681879160000},"page":"225-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stereotactic body radiotherapy for mediastinal lymph node with CyberKnife\u00ae: Efficacy and toxicity"],"prefix":"10.1016","volume":"27","author":[{"given":"A.","family":"Camps-Malea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Pointreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chapet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Calais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Barillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2022.11.002_bib0225","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.bulcan.2019.09.011","article-title":"Radioth\u00e9rapie st\u00e9r\u00e9otaxique\u00a0: changement de monde ou effet de mode\u00a0?","volume":"107","author":"Vallard","year":"2020","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.canrad.2022.11.002_bib0230","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fonc.2019.00543","article-title":"A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: where will the evidence lead?","volume":"9","author":"Al-Shafa","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0235","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.2008.21.7299","article-title":"Using a bigger hammer: the role of stereotactic body radiotherapy in the management of oligometastases","volume":"27","author":"Ben-Josef","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0240","doi-asserted-by":"crossref","first-page":"i58","DOI":"10.1093\/jrr\/rrw006","article-title":"Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach","volume":"57","author":"Ricardi","year":"2016","journal-title":"J Radiat Res (Tokyo)"},{"key":"10.1016\/j.canrad.2022.11.002_bib0245","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00066-013-0345-y","article-title":"CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer: a prospective evaluation of 95 patients\/118 lesions","volume":"189","author":"Jereczek-Fossa","year":"2013","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0255","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1634\/theoncologist.2012-0092","article-title":"Review and uses of stereotactic body radiation therapy for oligometastases","volume":"17","author":"Alongi","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.canrad.2022.11.002_bib0260","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0265","doi-asserted-by":"crossref","first-page":"20160251","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0270","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/cancers11020133","article-title":"Stereotactic radiotherapy for oligometastasis","volume":"11","author":"Otake","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2022.11.002_bib0275","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1471-2407-12-305","article-title":"Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial","volume":"12","author":"Palma","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2022.11.002_bib0280","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2022.11.002_bib0285","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12885-020-06876-4","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial","volume":"20","author":"Olson","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2022.11.002_bib0290","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2022.11.002_bib0295","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.prro.2011.11.007","article-title":"Radiotherapy for hilar or mediastinal lymph node metastases after definitive treatment with stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer","volume":"2","author":"Manabe","year":"2012","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0300","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.rpor.2014.10.004","article-title":"Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?","volume":"20","author":"Jereczek-Fossa","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.canrad.2022.11.002_bib0305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13014-017-0820-1","article-title":"Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases","volume":"12","author":"Yeung","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0310","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818803597","article-title":"Stereotactic radiotherapy for oligometastases in lymph nodes-a review","volume":"17","author":"Matsushita","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.canrad.2022.11.002_bib0315","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10585-018-9922-x","article-title":"Locoregional control and survival after lymph node SBRT in oligometastatic disease","volume":"35","author":"Loi","year":"2018","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.canrad.2022.11.002_bib0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10585-020-10071-x","article-title":"Systematic review of stereotactic body radiotherapy for nodal metastases","volume":"38","author":"Deodato","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.canrad.2022.11.002_bib0325","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.3389\/fonc.2020.616494","article-title":"Stereotactic body radiotherapy for lymph node oligometastases: real-world evidence from 90 consecutive patients","volume":"10","author":"Burkon","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0330","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0335","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0340","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1080\/0284186X.2018.1486040","article-title":"Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a \u201cno-fly zone\u201d?","volume":"57","author":"Jereczek-Fossa","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0345","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ijrobp.2018.10.008","article-title":"Stereotactic radiation for ultra-central lung tumors: good idea, or ultra-risky?","volume":"103","author":"Palma","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0350","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ijrobp.2008.08.001","article-title":"Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer","volume":"72","author":"Chang","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0355","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2014.08.008","article-title":"Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy","volume":"90","author":"Modh","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0360","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/JTO.0000000000000260","article-title":"Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors","volume":"9","author":"Nishimura","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0365","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: a systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0370","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.radonc.2013.01.004","article-title":"Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review","volume":"106","author":"Senthi","year":"2013","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0375","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0380","doi-asserted-by":"crossref","first-page":"18135","DOI":"10.18632\/oncotarget.7636","article-title":"Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canrad.2022.11.002_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.10.014","article-title":"Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers","volume":"115","author":"Horne","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2022.11.002_bib0390","doi-asserted-by":"crossref","first-page":"20181026","DOI":"10.1259\/bjr.20181026","article-title":"Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?","volume":"92","author":"Franceschini","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2020.07.1202","article-title":"Stereotactic body radiation therapy for mediastinal and hilar lymph node metastases","author":"Shahi","year":"2020","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0400","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1378\/chest.111.6.1718","article-title":"Regional lymph node classification for lung cancer staging","volume":"111","author":"Mountain","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.canrad.2022.11.002_bib0405","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.canrad.2022.11.002_bib0410","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0415","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00066-018-1416-x","article-title":"ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams: Statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery","volume":"195","author":"Wilke","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0420","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.canrad.2003.12.002","article-title":"Index de conformation et radioth\u00e9rapie","volume":"8","author":"Feuvret","year":"2004","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"10.1016\/j.canrad.2022.11.002_bib0425","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2147\/CMAR.S287993","article-title":"Clinical outcomes and prognostic factors of salvage stereotactic body radiotherapy for post-surgical thoracic oligo-recurrence\/metastasis of non-small-cell lung cancer","volume":"13","author":"Li","year":"2021","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.canrad.2022.11.002_bib0430","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.11.002_bib0435","doi-asserted-by":"crossref","first-page":"2280287","DOI":"10.21037\/jtd.2020.03.112","article-title":"Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review","volume":"12","author":"Tjong","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.canrad.2022.11.002_bib0440","doi-asserted-by":"crossref","first-page":"15690","DOI":"10.18632\/oncotarget.3704","article-title":"Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer","volume":"6","author":"Meng","year":"2015","journal-title":"Oncotarget"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823000525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823000525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:36:15Z","timestamp":1761136575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823000525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1278321823000525"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2022.11.002","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiotherapy for mediastinal lymph node with CyberKnife\u00ae: Efficacy and toxicity","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2022.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}